Mandate

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.

 The listing reflects the transformation we have executed over the past three years. We have built a scalable platform delivering efficiency, solid credit performance and earnings growth versus our Nordic consumer finance peers. Redomiciling to Sweden reduces capital requirements and levels the playing field, said Øyvind Oanes, CEO of Morrow Bank.

Vinge’s team consisted of Emma Stuart-Beck, Elias Bohlin, Henrik Schön, Caroline Krassén, David Flodin, Ebba Gäbel and Felicia Sandén (Financial Services), Rikard Lindahl, Joel Magnusson, Carl Lexenberg and Julia Jönsson (Corporate Public), as well as Siri Blomberg (IT&GDPR), Sam Seddigh, Alice Göransson and Louisa Fagarasan (Employment), Ian Jonsson and Filippa Eriksson (IP), Hedvig Ekdahl and Therese Baltzarsson (Commercial Agreements), Hedvig Merkel (Real Estate), Victor Ericsson, Maria Schultzberg and Vilma Henriksson (Tax), Diana Kanold and Alice Vångell (VDR).

Read the client's press release here and here.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026